Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 8/20 | 0.65 |
| ▸ | TMIGD3 | P0DMS9 | 4/20 | 0.56 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.56 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.56 |
| ▸ | PDE4A | P27815 | 2/20 | 0.53 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.53 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.53 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.53 |
| ▸ | CDK1 | P06493 | 1/20 | 0.52 |
| ▸ | PDE8A | O60658 | 6/20 | 0.52 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.51 |
| ▸ | PI4KA | P42356 | 1/20 | 0.50 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.50 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.50 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.50 |
| ▸ | PNP | P00491 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2060472 | 0.87 | PDE4A (0.67) | ADORA2AADORA1PDE4APDE4BPDE4C | |
| SCHEMBL5161967 | 0.86 | ADORA2A (0.53) | ADORA2ATMIGD3ADORA1ADORA2BPDE4A | |
| SCHEMBL5160796 | 0.84 | PDE8A (0.59) | ADORA2ATMIGD3ADORA1ADORA2BCDK1 | |
| SCHEMBL12537281 | 0.82 | ADORA2A (0.57) | ADORA2ATMIGD3ADORA1ADORA2BPDE4A | |
| SCHEMBL3441064 | 0.81 | YTHDC1 (0.53) | ADORA2ATMIGD3ADORA1ADORA2BPDE4A | |
| SCHEMBL5161857 | 0.81 | ADORA2A (0.61) | ADORA2ATMIGD3ADORA1ADORA2BPDE4A | |
| SCHEMBL5162437 | 0.81 | ADORA2A (0.61) | ADORA2ATMIGD3ADORA1ADORA2BPDE4A | |
| SCHEMBL5161127 | 0.80 | ADORA2A (0.85) | ADORA2ATMIGD3ADORA1ADORA2BCDK1 | |
| SCHEMBL5163121 | 0.80 | ADORA2A (0.60) | ADORA2ATMIGD3ADORA1ADORA2BPDE4A | |
| SCHEMBL1230786 | 0.79 | ADORA2A (1.00) | ADORA2AADORA1ADORA2BPI4KAPI4K2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2200615-A1 | A3 ADENOSINE RECEPTOR ANTAGONISTS | Gilead Palo Alto, Inc. (US) | 2010-06-30 | — | — | EP | disclosed |
| WO-2009052310-A1 | A3 ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC (US) | 2009-04-23 | — | — | WO | disclosed |
| US-20090099212-A1 | A3 ADENOSINE RECEPTOR ANTAGONISTS | ZABLOCKI JEFF | 2009-04-16 | — | — | US | disclosed |
| US-7238700-B2 | A2B adenosine receptor antagonists | CV THERAPEUTICS, INC. (US) | 2007-07-03 | — | — | US | disclosed |
| US-7189730-B2 | A2A adenosine receptor antagonists | CV THERAPEUTICS, INC. (US) | 2007-03-13 | — | — | US | disclosed |
| EP-1456209-B1 | A2A ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS INC (US) | 2007-02-28 | — | — | EP | disclosed |
| EP-1401837-B1 | PURINE DERIVATIVES AS A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS INC (US) | 2005-10-19 | — | — | EP | disclosed |
| US-20040209899-A1 | A2B adenosine receptor antagonists | PALLE VENKATA (IN) | 2004-10-21 | — | — | US | disclosed |
| EP-1456209-A1 | A2A ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2004-09-15 | — | — | EP | disclosed |
| US-6770651-B2 | THERAPY FOR ASTHMA, DIARRHEA | PALLE VENKATA (US) | 2004-08-03 | — | — | US | disclosed |
| EP-1401837-A1 | PURINE DERIVATIVES AS A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2004-03-31 | — | — | EP | disclosed |
| US-20030149060-A1 | A2A adenosine receptor antagonists | CV THERAPEUTICS, INC. | 2003-08-07 | — | — | US | disclosed |
| WO-2003051882-A1 | A2A ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2003-06-26 | — | — | WO | disclosed |
| US-20030064999-A1 | A2B adenosine receptor antagonists | PALLE VENKATA (US) | 2003-04-03 | — | — | US | disclosed |
| WO-2003006465-A1 | PARTIAL AND FULL AGONIST OF A ADENOSINE RECEPTORS | CV THERAPEUTICS, INC. (US) | 2003-01-23 | — | — | WO | disclosed |
| WO-2003002566-A1 | PURINE DERIVATIVES AS A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2003-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030064999-A1 | A2B adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA1 | ADORA2A 2/4885TMIGD3 2403/4885ADORA1 3/4885 |
| US-20090099212-A1 | A3 ADENOSINE RECEPTOR ANTAGONISTS | ADORA3, ADORA2A, ADORA2B | ADORA2A 2/4885TMIGD3 2761/4885ADORA1 4/4885 |
| US-20040209899-A1 | A2B adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA1 | ADORA2A 2/4885TMIGD3 4245/4885ADORA1 3/4885 |
| US-20030149060-A1 | A2A adenosine receptor antagonists | ADORA2A, ADORA2B, ADORA3 | ADORA2A 1/4885TMIGD3 1730/4885ADORA1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.